Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Cumberland Pharmaceuticals Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Cumberland Pharmaceuticals Inc. (CPIX) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX).
On October 23, 2026, Cumberland announced top-line results from its Phase 2a ASSIST-SSc clinical trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). While the Company emphasized that the drug was well tolerated and achieved its primary safety objective, observers noted that the pilot study offered no clear efficacy signal. Because a majority of subjects in both the treatment and placebo groups experienced limited disease progression during the study, the 41-patient trial lacked the statistical power to detect a meaningful treatment difference, rendering efficacy conclusions impossible. On this news, Cumberland’s stock price fell $4.14 per share, or 48.76%, to close at $4.35 per share on October 26, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether Cumberland Pharmaceuticals Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Cumberland Pharmaceuticals Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should Cumberland Pharmaceuticals Inc. (CPIX) Investors Do?
How Is Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) Stock Trading Today?
Interactive chart showing the weekly share price history of NASDAQ:CPIX (NASDAQ:CPIX).
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”